Abstract: In a process for the quantitative optical analysis of fluorescently labelled biological cells 5, a cell layer on a transparent support at the bottom 2 of a reaction vessel 1 is in contact with a solution 3 containing the fluorescent dye 4. The sensitivity of analytical detection can be considerably improved if to the fluorescent dye 4 already present in addition a masking dye 9, which absorbs the excitation light 6 for the fluorescent dye 4 and/or its emission light 7, is added to the solution 3 and/or if a separating layer 10 permeable to the solution and absorbing and/or reflecting the excitation light 6 or the emission light 7 is applied to the cell layer at the bottom 2. This process can also be used for improving the sensitivity in the quantitative optical analysis of a luminescent biological cell layer. The separating layer 10 must in this case be composed such that it has a high power of reflection for the luminescent light 11.

Abstract: The present invention relates to combinations of A) oxazolidinones of the formula (I), with B) antiarrhythmics, processes for the production of these combinations, their use for the prophylaxis and/or treatment of diseases, and their use for the manufacture of medicaments for the prophylaxis and/or treatment of diseases, especially of thromboembolic disorders and/or complications.

Abstract: The present invention relates to the use of substituted 2-thio-3,5-dicyano-4-phenyl-6-amino-pyridines of the formula (I) for production of a medicament for the prophylaxis and/or treatment of nausea and vomiting.

Abstract: The present invention relates to substituted 2,6-diamino-3,5-dicyano-4-arylpyridines of the formula (I) wherein the definitions of substituent groups R1-R7 are as provided in the specification and claims, to a pharmaceutical composition containing such a compound, to a process for preparation of such materials, and to their use as medicaments for the treatment of cardiovascular disorders and diabetes.

Abstract: The invention relates to compounds of general formula (I), a method for the production thereof and the use thereof as pharmacologically effective substances for a broad medical indication spectrum. Furthermore, selective adenosine receptor ligands, preferably selective adenosine A1-, adenosine A2a- and/or adenosine A2b-receptor ligands are provided for the prophylaxis and/or the treatment of diseases, especially cardiovascular diseases, diseases of the urogenital region, diseases of the respiratory tract, inflammatory and neuroinflammatory diseases, diabetes, especially pancreatic diabetes, neurodegenerative diseases, pain states, cancer as well as liver fibrosis and liver cirrhosis.

Abstract: In a process for the quantitative optical analysis of biological cells labelled with a fluorescent dye, the sensitivity of analytical detection can be considerably improved if a masking dye, which absorbs the excitation light for the fluorescent dye and/or its emission light is added to the solution surrounding the biological cells and/or if a separating layer permeable to the solution and absorbing and/or reflecting the excitation light or the emission light is applied to a layer of the biological cells at the bottom of a reaction vessel. This process can also be used for improving the sensitivity in the quantitative optical analysis of a luminescent biological cell layer. Analogously, these process principles can also be used in receptor studies for the masking of the interfering background radiation in the quantitative optical analysis of fluorescently or luminescently labelled reaction components.

Abstract: This application relates to compounds of formula (I), wherein R1, R2, R3, and R4 are defined as recited in the claims, or a tautomer, salt, hydrate, or alkoxide thereof. A process for preparing such materials, pharmaceutical compositions containing them, and methods of treating a cardiovascular disorder by administering them to a patient are also disclosed and claimed.

Abstract: This application relates to compounds of the formula wherein the groups R1–R6 are as defined in the specification and claims, and to a pharmaceutical composition containing the same, and to a method of using the same in treatment of cardiovascular disorders.

Abstract: This application relates to compounds of formula (I) below in which the several variable groups are as defined in the specification and claims, to methods of preparing these materials, to pharmaceutical compositions containing these materials, and to methods of using these materials to treat ischaemia or reperfusion damage.

Abstract: Compounds of the formula (I) a process for their preparation and their use as medicaments are described.

Abstract: Compounds of the formula (I) a process for their preparation and their use as medicaments are described.

Abstract: The present invention relates to the use of 2,5-diamidoindole derivatives for the preparation of medicaments for treating urological disorders in humans and/or animals.

Abstract: This application relates to pyridine derivatives having the general structure in which the several variables are as defined in the specification and claims, and to a process for preparing these compounds, a pharmacutical composition containing such compounds, and a method for using these materials for treatment of stable and unstable angina pectoris and atrial fibrillation.

Abstract: The invention relates to the compounds of formula (I), to a method for producing the same and to the use thereof as medicaments.

Abstract: The present invention relates to substituted phenylcyclohexanecarboxamides of the formula (I) to processes for their preparation and to their use in medicaments, in particular for the prevention and/or treatment of cardiovascular disorders.

Abstract: The invention relates to compounds of formula (I), to a method for the production thereof, and to the use of the same as pharmaceuticals for the treatment of diseases in humans and/or animals

Abstract: Compounds of the formula (I) a process for preparing them, and their use as medicaments are described.

Abstract: A method and a device are used for carrying out measurements on cells located in a liquid environment. Each cell is positioned with an underside of its membrane on a surface having a channel running through it. A negative pressure is established to aspirate the cells. Each cell is electrically scanned via at least one electrode which is spaced apart from the cell. The negative pressure is preferably established in a pulse-like manner to rupture the membrane in such a way that the cell interior enclosed by the membrane is connected to the channel.

Abstract: The present invention relates to substituted phenylcyclohexanecaboxamides of the formula (I), to processes for their preparation and to their use in medicaments, in particular for treating cardiovascular disorders.

Abstract: The use of compounds of formula (I) as medicaments, novel compounds of formula (I) and a method for production thereof are disclosed. Compounds of formula (I) are effective as adenosine receptor ligands.